Targeting YAP/TAZ in Combination with PD-L1 Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (NSCLC)

The survival of non-small cell lung cancer (NSCLC) patients has improved in the last decade as a result of introducing new therapeutics, such as immune checkpoint inhibitors, in the clinic. Still, some NSCLC patients do not benefit from these therapies due to intrinsic resistance or the development...

Descripción completa

Detalles Bibliográficos
Autores principales: Papavassiliou, Kostas A., Marinos, Georgios, Papavassiliou, Athanasios G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10047112/
https://www.ncbi.nlm.nih.gov/pubmed/36980211
http://dx.doi.org/10.3390/cells12060871

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10047112/
https://www.ncbi.nlm.nih.gov/pubmed/36980211
http://dx.doi.org/10.3390/cells12060871

Ejemplares similares